[1]庄永志综述,王俊杰审校.放射性粒子治疗前列腺癌后泌尿系统并发症及其相关因素的研究现状[J].中国微创外科杂志,2007,07(2):139-140.
点击复制

放射性粒子治疗前列腺癌后泌尿系统并发症及其相关因素的研究现状()
分享到：

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
07
期数:
2007年2期
页码:
139-140
栏目:
文献综述
出版日期:
2007-02-20

文章信息/Info

作者:
庄永志综述; 王俊杰审校
大庆油田总医院肿瘤治疗中心，大庆163001
分类号:
R737.25;R730.6;R817.8
文献标志码:
A

参考文献/References:

[1]Pellizzon AC, Salvajoli JV, Maia MA, et al. Late urinary morbidity with high dose prostate brachytherapy as a boost to conventional external beam radiation therapy for local and locally advanced prostate cancer. J Urol, 2004, 171(3):1105-1108.
[2]王俊杰，庄永志.放射性粒子近距离治疗肿瘤.中国微创外科杂志, 2001, 1(3):187-191.
[3]Borchers H, KirschnerHermanns R, Brehmer B et al. Permanent 125Iseed brachytherapy or radical prostatectomy: a prospective comparison considering oncological and quality of life results. BJU Int, 2004, 94(6):805-811.
[4]Merrick GS, Butler WM, Wallner KE, et al. Longterm urinary quality of life after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys, 2003, 56:454-461.
[5]Wallner K，Roy J，Harrion L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I125 prostate brachytherapy. Int J Radiat Oncol Biol Phys, 1995, 32(2):465-471.
[6]Zelefsky MJ, Yamada Y, Marion C, et al. Improved conformality and decreased toxicity with intraoperative computeroptimized transperineal ultrasoundguided prostate brachytherapy. Int J Radiat Oncol Biol Phys, 2003, 55:956-963.
[7]McElveen TL, Waterman FM, Kim H, et al. Factors predicting for urinary incontinence after prostate brachytherapy. Int J Radiat Oncol Biol Phys, 2004, 59 (5):1395-1404.
[8]Locke J, Ellis W, Wallner K, et al. Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: A prospective study. Int J Radiat Oncol Biol Phys, 2002, 52:712-719.
[9]Bucci J, Morris WJ, Keyes M, et al. Predictive factors of urinary retention following prostate brachytherapy. Int J Radiat Oncol Biol Phys, 2002, 53:91-98.
[10]Terk MD, Stock RG, Stone NN. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol, 1998, 160(4):1379-1382.
[11]Merrick GS, Butler WM, Wallner KE, et al. Prophylactic versus therapeutic alphablockers after permanent prostate brachytherapy. Urology, 2002, 60:650-655.
[12]Merrick GS, Butler WM, Lief JH, et al. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys, 2000, 47:121-128.
[13]Gutman S, Merrick GS, Butler WM, et al. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy. BJU Int, 2006, 97(1):62-68.
[14]Niehaus A, Merrick GS, Butler WM, et al. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys, 2006, 64(1):136-143.
[15]Kollmeier MA Stock RG, Cesaretti J, et al. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy. J Urol, 2005, 173(3):808-812.
[16]Narayana V, Troyer S, Evans V, et al. Randomized trial of highand lowsource strength (125)I prostate seed implants. Int J Radiat Oncol Biol Phys, 2005, 62(3): 941-942.

更新日期/Last Update: 2013-11-15